2026-04-17T06:17:27Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/73152025-10-01T01:31:57Zcom_2072_378071com_2072_378040col_2072_378097

Improvement of functional neurological disorder after administration of esketamine nasal spray: a case report Soto Angona, Oscar Rodríguez Urrutia, Amanda Arteaga Henriquez, Gara Vendrell Serres, Júlia Ramos-Quiroga, Josep Antoni Sistema nerviós - Malalties - Tractament Aerosolteràpia Resistència als medicaments DISEASES::Nervous System Diseases Other subheadings::Other subheadings::Other subheadings::/drug therapy CHEMICALS AND DRUGS::Complex Mixtures::Colloids::Aerosols::Nasal Sprays PSYCHIATRY AND PSYCHOLOGY::Mental Disorders::Mood Disorders::Depressive Disorder::Depressive Disorder, Treatment-Resistant ENFERMEDADES::enfermedades del sistema nervioso Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia COMPUESTOS QUÍMICOS Y DROGAS::mezclas complejas::coloides::aerosoles::aerosoles nasales PSIQUIATRÍA Y PSICOLOGÍA::trastornos mentales::trastornos del humor::trastorno depresivo::trastorno depresivo resistente al tratamiento Esketamina; Trastorn neurològic funcional; Paràlisi mixta Esketamina; Trastorno neurológico funcional; Parálisis mixta Esketamine; Functional neurological disorder; Mixed paralysis Functional neurological disorder (FND) is a complex neuropsychiatric condition characterized by the presence of neurological symptoms and signs (either motor or sensory) that cannot be explained by any known medical or mental disease. It is frequently presented with psychiatric comorbidities, such as major depression. Its prognosis is poor, with low improvement or recovery rates at 1 year after their onset, and no particular treatment has demonstrated significant efficacy in this regard. Here, we describe the management of a patient affected by treatment-resistant depression (TRD) and FND characterized by mixed paralysis (sensory and motor) in the left arm, and who was successfully treated with esketamine nasal spray, achieving remission in both disorders. The US Food and Drug Administration and the European Medicines Agency recently approved esketamine, the S-enantiomer of ketamine, for treatment of TRD. It is a fast-acting drug that provides a rapid-onset improvement of depressive symptoms. We have presented the first case, to our knowledge, of functional neurological symptoms being successfully treated with esketamine in a patient with comorbid TRD. While the novelty of this data implies a clear need for further research, it is suggested that esketamine might be a useful tool for the treatment of FND, acting through different theorized mechanisms that are in tune with recent advances in knowledge of the etiopathology of FND. The authors received no financial support for the research, authorship, and/or publication of this article. 2022-04-06T11:03:44Z 2022-04-06T11:03:44Z 2021-01 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Therapeutic Advances in Psychopharmacology;11 https://doi.org/10.1177/20451253211022187 Attribution-NonCommercial 4.0 International http://creativecommons.org/licenses/by-nc/4.0/ info:eu-repo/semantics/openAccess SAGE Publications Scientia